Gaucher Disease Type 1 (GD1)
GD1 is an autosomal recessive lysosomal storage disorder caused by biallelic GBA mutations leading to glucocerebrosidase deficiency. Accumulated glucocerebroside in macrophages causes hepatosplenomegaly, cytopenias, bone disease, and fatigue. Unlike types 2/3, GD1 lacks primary CNS involvement.
Symptoms & Signs
- Hepatosplenomegaly, abdominal distention
- Thrombocytopenia (easy bruising), anemia (fatigue)
- Bone pain, crises, osteonecrosis, fractures, Erlenmeyer flask deformities
- Growth delay, delayed puberty
- Pulmonary hypertension (rare)
- Increased risk of Parkinson disease and multiple myeloma
Diagnosis
- Enzyme assay showing low glucocerebrosidase activity
- GBA gene sequencing for mutation confirmation
- Biomarkers: chitotriosidase, lyso-Gb1 (monitoring)
- Imaging: MRI for bone marrow infiltration, liver/spleen volumes
- Family screening and genetic counseling
Treatment Options
Enzyme Replacement Therapy (ERT)
- Imiglucerase, velaglucerase alfa, taliglucerase alfa IV every 2 weeks
- Improve organomegaly, cytopenias, bone disease
- Monitor for infusion reactions, antibody formation
Substrate Reduction Therapy (SRT)
- Eliglustat (oral) for CYP2D6 extensive/intermediate metabolizers
- Miglustat (less used due to GI/neurologic side effects)
- Consider when ERT not feasible or as adjunct
Supportive Care
- Treat bone pain with analgesics, bisphosphonates if needed
- Manage anemia/thrombocytopenia, avoid splenectomy if possible
- Vaccinations (pneumococcal, influenza, COVID-19)
- Screen for Parkinson symptoms and malignancy risk
Living with GD1
- Track enzyme infusions or oral therapy, labs (hemoglobin, platelets, chitotriosidase), organ volumes, bone scans, symptoms, and side effects
- Maintain healthy weight, bone-friendly diet/exercise
- Monitor for pregnancy planning (ERT can continue during pregnancy with specialist guidance)
- Connect with Gaucher support networks for resources
Complications
- Bone crises, osteonecrosis, fractures
- Pulmonary hypertension, liver fibrosis
- Parkinson disease risk (need neurologic monitoring)
- Potential infusion or SRT side effects (GI, neuropathy)
Research & Future Directions
Gene therapy, substrate reduction combinations, and small-molecule chaperones (ambroxol) aim to reduce treatment burden.
Experimental & Emerging Treatments
- Gene Therapy: Lentiviral or AAV vectors delivering functional GBA.
- Pharmacological Chaperones: Ambroxol and other compounds stabilizing misfolded enzyme.
- Combination ERT+SRT to optimize organ response with lower doses.
- Digital Biomarkers: Wearable sensors for pain/mobility to fine-tune therapy.
Track GD1 with Diagnoza.care
Keep Organs & Bones in Balance – Log infusion schedules, oral SRT doses, lab biomarkers, imaging, bone pain, fractures, neurologic screening, and specialist visits; capture side effects; and let the AI companion remind you of labs and symptom monitoring to adjust therapy quickly.
Medical Disclaimer: Informational only. Work with your metabolic specialist for therapy selection, dosing adjustments, and multidisciplinary monitoring.
Sources: National Gaucher Foundation, American College of Medical Genetics, European Working Group on Gaucher Disease